Stifel Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $9

Benzinga Newsdesk www.benzinga.com Positive 65.1%

Neg 0% Neu 0% Pos 65.1%

Stifel analyst Dara Azar initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Buy rating and announces Price Target of $9.